登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002946 证券简称：新乳业 公告编号：2025-055 债券代码：128142 债券简称：新乳转债 新希望乳业股份有限公司 关于可转换公司债券2025年付息公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、"新乳转债"将于2025年12月18日按面值支付第五年的利息，每10张"新乳转债"（面值1,000.00元）利 息为18.00元（含税）。 2、债权登记日：2025年12月17日。 新希望乳业股份有限公司（以下简称"公司"或"本公司"）于2020年12月18日公开发行了718万张可转换 公司债券，每张面值100元，发行总额71,800万元。根据《新希望乳业股份有限公司公开发行A股可转换 公司债券募集说明书》（以下简称"《可转债募集说明书》"）有关条款规定，在"新乳转债"的计息期 内，每年付息一次，现将"新乳转债"2024年12月18日至2025年12月17日期间的付息事项公告如下： 一、可转换公司债券基本情况 1、债券代码：128142 2、债券简称：新乳转债 3、可转换公司 ...

证券时报·数据宝统计，中国飞鹤在港交所公告显示，12月11日以每股4.08港元的价格回购196.90万股， 回购金额达803.35万港元。该股当日收盘价4.090港元，下跌1.68%，全天成交额7379.44万港元。 （文章来源：证券时报网） 自10月24日以来公司已连续34日进行回购，合计回购2.29亿股，累计回购金额9.71亿港元。 其间该股累 计上涨1.74%。 今年以来该股累计进行36次回购，合计回购2.31亿股，累计回购金额9.81亿港元。（数据宝） 中国飞鹤回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.12.11 | 196.90 | 4.080 | | 803.35 | | 2025.12.10 | 547.00 | 4.200 | 4.120 | 2293.91 | | 2025.12.09 | 800.70 | 4.120 | 4.070 | 3292.83 | | 2025.12.08 | 700.00 | 4.130 | 4.090 | 2 ...

Core Viewpoint - Feihe and JD.com have launched two groundbreaking products, Jicui and Qicui, marking a significant innovation in the infant nutrition sector, aimed at meeting the nutritional needs of Chinese babies and leading the industry into a new era of "breast milk-like formula + fresh active technology" [1][3]. Group 1: Product Innovation - The new products focus on "fresh active nutrition," addressing core consumer demands, with 78% of educated mothers prioritizing "active nutrition" and "good absorption" when selecting infant formula [3]. - Feihe's innovation includes the first-ever integration of "fresh raw materials" into the freshness standard of infant formula, creating a closed-loop system from fresh sources to self-produced active ingredients [3][5]. Group 2: Production and Quality - Feihe has achieved self-production capabilities for 11 key raw materials, enhancing freshness by at least 23 times and demonstrating a 6.4 times improvement in absorption [5]. - The products utilize fresh raw materials produced within 30 days, significantly reducing the freshness timeline from years to days, with proprietary extraction techniques ensuring superior quality [5][10]. Group 3: Research and Development - Feihe has established one of China's largest breast milk databases and leads national initiatives in breast milk research, accumulating significant findings that inform product development [8]. - The company holds three leading positions in the industry: first in breast milk research achievements, first in infant formula patents, and first in maternal source nutrition branding [8][10]. Group 4: Clinical Validation - Feihe adheres to a "clinical first, market second" approach, conducting rigorous clinical trials before product launch, ensuring high standards of evidence for the efficacy of Jicui and Qicui [13]. - The clinical trials utilized RCT (randomized controlled trial) designs, achieving compliance with the highest global standards, thus validating the products' nutritional claims [13][16]. Group 5: Nutritional Benefits - Jicui's formula emphasizes a dual-source protective system, enhancing the baby's gut health and immune system, with evidence showing a 10.6% increase in the baby's immunoglobulin sIgA levels [10][17]. - Qicui focuses on brain development, incorporating a unique nutritional structure that mimics breast milk, leading to significant improvements in sleep patterns and cognitive development metrics [12][17]. Group 6: Market Positioning - The launch of Jicui and Qicui represents not just a formula upgrade but a strategic innovation tailored for Chinese infants, setting a new value benchmark in the infant formula industry [17]. - Feihe aims to continue providing products that support scientific nutrition, contributing to the future potential of children and the nation [17].

阳光乳业（001318）(001318.SZ)发布公告，控股股东江西阳光乳业集团有限公司的一致行动人南昌致 合企业管理中心(有限合伙)(以下简称"南昌致合")计划自本公告发布之日起15个交易日后的三个月内(即 2026年1月8日至2026年4月7日)通过集中竞价交易方式合计减持不超过2,826,600股，即不超过公司总股 本的1%;通过大宗交易方式减持不超过5,653,200股，即不超过公司总股本的2%。 ...

阳光乳业12月11日公告，公司控股股东一致行动人南昌致合企业管理中心（有限合伙）计划自本公告发 布之日起15个交易日后的三个月内（即2026年1月8日至2026年4月7日），通过集中竞价交易方式减持不 超过282.66万股，即不超过公司总股本的1%；通过大宗交易方式减持不超过565.32万股，即不超过公司 总股本的2%。 ...

阳光乳业公告，公司股东南昌致合企业管理中心（有限合伙）计划自公告发布之日起15个交易日后的三 个月内，即2026年1月8日至2026年4月7日，通过集中竞价交易方式减持不超过282.66万股，占公司总股 本的1%；通过大宗交易方式减持不超过565.32万股，占公司总股本的2%。合计减持不超过847.98万 股，占公司总股本的3%。减持原因为满足股东自身资金需要，减持价格将根据市场价格及交易方式确 定，不低于公司首次公开发行股票的发行价。 ...

Core Viewpoint - Mengniu Dairy (02319) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company plans to repurchase 200,000 shares at a cost of HKD 2.85 million [1] - The buyback is scheduled for December 11, 2025, reflecting a strategic move to enhance shareholder value [1]

Core Viewpoint - Mengniu Dairy (02319) announced a share buyback plan, committing to repurchase 200,000 shares for a total expenditure of HKD 2.85 million, scheduled for December 11, 2025 [1] Summary by Category - **Company Actions** - The company plans to repurchase 200,000 shares at a cost of HKD 2.85 million [1]

（文章来源：证券日报） 证券日报网讯 12月11日，新乳业在互动平台回答投资者提问时表示，截至2025年12月10日公司股东总 户数为17100户。 ...

Core Viewpoint - Mengniu Group's flagship brand Youyi C has achieved a significant milestone by obtaining the "Health Food Registration Certificate" from the National Market Supervision Administration, marking its transition from a regular beverage to a health food [2][3]. Group 1: Product Development and Certification - The journey to obtaining the "Health Food Registration" for Youyi C spanned twelve years, starting in 2013, during which the research team addressed challenges related to probiotic stability, synergy between prebiotics and probiotics, and balancing taste with efficacy [3]. - The Youyi C product is set to be launched in 2026, featuring two core health functions: "helps regulate intestinal flora" and "aids digestion," which have been recognized for their safety, stability, and functionality by national authorities [2][3]. Group 2: Industry Position and Recognition - Youyi C is not the first product from Mengniu to receive the "Health Food Registration"; previously, Mengniu's Guanyirun yogurt became the first yogurt product in China to obtain this certification, showcasing the company's leadership in functional health foods [5]. - Mengniu has received multiple prestigious awards for its research in the field of probiotics, including the National Science and Technology Progress Award and the China Patent Silver Award, highlighting its commitment to innovation [5]. Group 3: Consumer Impact and Future Direction - The certification of Youyi C represents a shift from traditional health products to more accessible beverage formats, providing consumers with a simple and effective health management option, thereby enhancing trust in probiotic beverages [7]. - Moving forward, Youyi C will continue to focus on probiotic technological innovation, aiming to lead the upgrade of functional dairy products and provide safer and more effective health support for Chinese families [8].